NO20053367L - Sigmareseptor-defisiente, mutante ikke-humane pattedyr og anvendelser derav. - Google Patents
Sigmareseptor-defisiente, mutante ikke-humane pattedyr og anvendelser derav.Info
- Publication number
- NO20053367L NO20053367L NO20053367A NO20053367A NO20053367L NO 20053367 L NO20053367 L NO 20053367L NO 20053367 A NO20053367 A NO 20053367A NO 20053367 A NO20053367 A NO 20053367A NO 20053367 L NO20053367 L NO 20053367L
- Authority
- NO
- Norway
- Prior art keywords
- receptor
- mutant
- deficient
- sigma
- sigmar
- Prior art date
Links
- 230000002950 deficient Effects 0.000 title abstract 4
- 108010085082 sigma receptors Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100028662 Sigma intracellular receptor 2 Human genes 0.000 abstract 1
- 101710109012 Sigma intracellular receptor 2 Proteins 0.000 abstract 1
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 abstract 1
- 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 abstract 1
- 230000036592 analgesia Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 238000000099 in vitro assay Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000005462 in vivo assay Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000003176 neuroleptic agent Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Oppfinnelsen angår et sigmareseptordefisient, mutant, ikke-humant pattedyr og anvendelser derav. Genomet av det ikke-humane, mutante pattedyr, defisient i en endogen sigmareseptor, inneholder en mutasjon som omfatter en disrupsjon i et endogent sigmareseptorgen, karakterisert ved at nevnte gendisrupsjon fører til en mutant som mangler påvisbare nivåer av endogen sigmareseptor. Mutanten kan brukes som et kontrolldyr for in vivo tester, så vel som en kilde av celler som kan anvendes i in vitro tester. Mutanter defisiente i sigma-l-reseptoren kan anvendes som modeller for in vivo studie av forstyrrelser av sentralnervesystemet, hukommelsesendringer, stresstilstander og medikamentavhengighet, analgesiprosesser og nevrobeskyttelse. Mutanter defisiente i sigma-2-reseptoren kan anvendes for å studere diagnostiske eller terapeutiske verktøy for å bekjempe kreft og/eller degenerative prosesser og/eller designe forbindelser i stand til å forebygge, redusere eller lindre den sekundære patologi forbundet med administrasjon av nevroleptiske midler.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200202815A ES2209650B2 (es) | 2002-12-09 | 2002-12-09 | Mamiferos no humanos mutantes deficientes en receptores sigma y sus aplicaciones. |
| PCT/ES2003/000624 WO2004052092A1 (es) | 2002-12-09 | 2003-12-09 | Mamíferos no humanos mutantes deficientes en receptores sigma y sus aplicaciones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20053367D0 NO20053367D0 (no) | 2005-07-11 |
| NO20053367L true NO20053367L (no) | 2005-07-11 |
Family
ID=32480022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053367A NO20053367L (no) | 2002-12-09 | 2005-07-11 | Sigmareseptor-defisiente, mutante ikke-humane pattedyr og anvendelser derav. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8003847B2 (no) |
| EP (2) | EP1584232B1 (no) |
| JP (1) | JP4515915B2 (no) |
| AR (1) | AR042300A1 (no) |
| AT (1) | ATE360362T1 (no) |
| AU (1) | AU2003285369C1 (no) |
| CA (1) | CA2508697A1 (no) |
| CY (1) | CY1106675T1 (no) |
| DE (1) | DE60313499T2 (no) |
| DK (1) | DK1584232T3 (no) |
| ES (2) | ES2209650B2 (no) |
| NO (1) | NO20053367L (no) |
| PT (1) | PT1584232E (no) |
| WO (1) | WO2004052092A1 (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| JP2009536667A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | ５ｈｔ受容体介在性の神経新生 |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| AU5431098A (en) | 1996-11-07 | 1998-05-29 | Wistar Institute Of Anatomy And Biology, The | Sparc-deficient transgenic mice |
| US6194633B1 (en) | 1998-01-26 | 2001-02-27 | University Of Iowa Research Foundation | Non-human animal having a functionally disrupted SLP-76 gene |
| US6207876B1 (en) | 1998-04-28 | 2001-03-27 | Board Of Regents, The University Of Texas System | Adenosine deaminase deficient transgenic mice and methods for the use thereof |
| US6252132B1 (en) | 1998-11-02 | 2001-06-26 | Institut Pasteur | Mutant mouse containing a knockout mutation in DNA encoding an endogenous alpha 4 subunit of nicotinic acetylcholine receptor |
| US6245965B1 (en) | 1999-01-29 | 2001-06-12 | St. Jude Children's Research Hospital | Knockout mice and cells that lack p19INK4d and p27KIP1 activity and methods of use thereof |
| US6245963B1 (en) | 1999-05-28 | 2001-06-12 | Academia Sinica | Knockout-transgenic mouse model of spinal muscular atrophy |
| JP4470077B2 (ja) * | 1999-11-16 | 2010-06-02 | 和男 鈴木 | 好中球走化性因子ｌｅｃｔ２遺伝子の機能が欠損したマウス |
-
2002
- 2002-12-09 ES ES200202815A patent/ES2209650B2/es not_active Expired - Fee Related
-
2003
- 2003-12-04 AR ARP030104478A patent/AR042300A1/es not_active Application Discontinuation
- 2003-12-09 ES ES03778357T patent/ES2286484T3/es not_active Expired - Lifetime
- 2003-12-09 EP EP03778357A patent/EP1584232B1/en not_active Expired - Lifetime
- 2003-12-09 EP EP06120550A patent/EP1752540A3/en not_active Withdrawn
- 2003-12-09 DE DE60313499T patent/DE60313499T2/de not_active Expired - Lifetime
- 2003-12-09 PT PT03778357T patent/PT1584232E/pt unknown
- 2003-12-09 DK DK03778357T patent/DK1584232T3/da active
- 2003-12-09 AU AU2003285369A patent/AU2003285369C1/en not_active Ceased
- 2003-12-09 AT AT03778357T patent/ATE360362T1/de active
- 2003-12-09 CA CA002508697A patent/CA2508697A1/en not_active Abandoned
- 2003-12-09 JP JP2004558125A patent/JP4515915B2/ja not_active Expired - Fee Related
- 2003-12-09 US US10/731,379 patent/US8003847B2/en not_active Expired - Fee Related
- 2003-12-09 WO PCT/ES2003/000624 patent/WO2004052092A1/es not_active Ceased
-
2005
- 2005-07-11 NO NO20053367A patent/NO20053367L/no not_active Application Discontinuation
-
2007
- 2007-06-25 CY CY20071100839T patent/CY1106675T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003285369B2 (en) | 2009-09-10 |
| US8003847B2 (en) | 2011-08-23 |
| JP4515915B2 (ja) | 2010-08-04 |
| JP2006508673A (ja) | 2006-03-16 |
| WO2004052092A1 (es) | 2004-06-24 |
| US20050132429A1 (en) | 2005-06-16 |
| ES2209650A1 (es) | 2004-06-16 |
| DE60313499D1 (de) | 2007-06-06 |
| ES2286484T3 (es) | 2007-12-01 |
| AU2003285369A1 (en) | 2004-06-30 |
| NO20053367D0 (no) | 2005-07-11 |
| HK1083987A1 (en) | 2006-07-21 |
| CY1106675T1 (el) | 2012-05-23 |
| EP1584232A1 (en) | 2005-10-12 |
| EP1584232B1 (en) | 2007-04-25 |
| ATE360362T1 (de) | 2007-05-15 |
| CA2508697A1 (en) | 2004-06-24 |
| PT1584232E (pt) | 2007-07-24 |
| AU2003285369C1 (en) | 2010-02-18 |
| DE60313499T2 (de) | 2008-01-03 |
| EP1752540A3 (en) | 2007-11-21 |
| EP1752540A2 (en) | 2007-02-14 |
| ES2209650B2 (es) | 2006-11-01 |
| DK1584232T3 (da) | 2007-07-30 |
| AR042300A1 (es) | 2005-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Girisha et al. | The homozygous variant c. 797G> A/p.(Cys266Tyr) in PISD is associated with a Spondyloepimetaphyseal dysplasia with large epiphyses and disturbed mitochondrial function | |
| Mirza et al. | Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists | |
| Martínez et al. | A genetic interaction between rap 1 and telomerase reveals an unanticipated role for rap 1 in telomere maintenance | |
| Homberg et al. | Serotonin transporter deficiency in rats improves inhibitory control but not behavioural flexibility | |
| Tie et al. | Evaluation of warfarin resistance using transcription activator‐like effector nucleases‐mediated vitamin K epoxide reductase knockout HEK293 cells | |
| Chen et al. | A chemical-genetic approach to studying neurotrophin signaling | |
| Blencke et al. | Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors | |
| Wolfgang et al. | The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasis | |
| König et al. | Mutations in the NSDHL gene, encoding a 3β‐hydroxysteroid dehydrogenase, cause CHILD syndrome | |
| Wadenberg | Conditioned avoidance response in the development of new antipsychotics | |
| Heydet et al. | A truncating mutation of Alms1 reduces the number of hypothalamic neuronal cilia in obese mice | |
| Verma et al. | NPY controls fear conditioning and fear extinction by combined action on Y1 and Y2 receptors | |
| Hill et al. | Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity | |
| NO20053367L (no) | Sigmareseptor-defisiente, mutante ikke-humane pattedyr og anvendelser derav. | |
| Pangrazio et al. | Exome sequencing identifies CTSK mutations in patients originally diagnosed as intermediate osteopetrosis | |
| Pal et al. | Alteration of JNK-1 signaling in skeletal muscle fails to affect glucose homeostasis and obesity-associated insulin resistance in mice | |
| Margutti et al. | Are MAP kinases drug targets? Yes, but difficult ones | |
| Ishikawa | Portrait of replication stress viewed from telomeres | |
| Smolen et al. | Quantitative proteomics and phosphoproteomics of PP2A-PPP2R5D variants reveal deregulation of RPS6 phosphorylation via converging signaling cascades | |
| Magini et al. | P5CS expression study in a new family with ALDH18A1‐associated hereditary spastic paraplegia SPG9 | |
| McCaul et al. | Deletion of mFICD AMPylase alters cytokine secretion and affects visual short-term learning in vivo | |
| Erickson et al. | Analysis of peripheral amyloid precursor protein in Angelman Syndrome | |
| Hansen‐Schwartz et al. | Protein kinase mediated upregulation of endothelin A, endothelin B and 5‐hydroxytryptamine 1B/1D receptors during organ culture in rat basilar artery | |
| Zhang et al. | Muscarinic receptor-mediated GTP–Eu binding in the hippocampus and prefrontal cortex is correlated with spatial memory impairment in aged rats | |
| Triggiani et al. | Differential modulation of mediator release from human basophils and mast cells by mizolastine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |